Last updated February 2nd 2015
Yissum Research Development Company of the Hebrew University of Jerusalem and an Australian medical cannabis company recently signed an exclusive licensing and collaboration agreement for the development, manufacturing and marketing of a novel delivery system to enhance the bioavailability of cannabidiol (CBD) and/or THC, the active ingredients in cannabis, for the treatment of a variety of medical indications.
The novel formulations are based on oral and transbuccal delivery technologies developed by Professors Abraham Domb and Amnon Hoffman from the Institute of Drug Research, School of Pharmacy, Faculty of Medicine, the Hebrew University of Jerusalem.
The Australian PhytoTech Medical will develop an improved, oral capsule formulation and transbuccal delivery system that consists of a flexible, muco-adhesive patch that will release the active ingredients of cannabis in a controlled manner.
“We are very pleased to collaborate with PhytoTech in developing the inventions of Professors Domb and Hoffman for the purpose of delivering the active components in cannabis. Medical cannabis is increasingly being used for a variety of indications, such as reducing nausea during chemotherapy and relieving pain and muscle spasticity in MS patients. Development of state-of-the-art delivery systems for the active ingredients will undoubtedly pave the way for a wider variety of clinical indications for these types of drugs,” said Yaacov Michlin, CEO of Yissum Research Development Company.
“We are happy to collaborate with Yissum in developing this novel delivery platform for THC and CBD,” said Boaz Wachtel, Managing Director of PhytoTech Medical. “We believe that Yissum’s novel transbuccal delivery method is particularly appropriate for the delivery of these agents, and helps avoid problems such as lack of standardization of drug concentration, and health risks stemming from more traditional ways of absorbing cannabis, such as smoking.”